Investigational Med Tied to Major Reduction in OSA Severity

26 Oct 2026 0 comments

In two phase 3 trials, retatrutide significantly reduced sleep apnea severity and produced substantial weight loss in adults with overweight and obesity, with or without comorbid type 2 diabetes.
Medscape Medical News

Source: Medscape Neurology Published 26 Oct 2026 Imported 26 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment